The effect of the modified Glasgow prognostic score in metastatic gastric cancer
Background: Metastatic gastric cancer (GC) is the third most common cause of cancer-related death. At the time of metastatic stage treatment is given for palliative purposes. Therefore parameters other than performance status are needed to determine the prognosis. Objectives: It is aimed demonstrat...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
South Valley University, Faculty of Medicine
2023-07-01
|
| Series: | SVU - International Journal of Medical Sciences |
| Subjects: | |
| Online Access: | https://svuijm.journals.ekb.eg/article_295352.html |
| Summary: | Background: Metastatic gastric cancer (GC) is the third most common cause of cancer-related death. At the time of metastatic stage treatment is given for palliative purposes. Therefore parameters other than performance status are needed to determine the prognosis.
Objectives: It is aimed demonstrate that the modified Glasgow Prognostic Score (mGPS) is prognostic factor for overall survival and mGPS is a sensitive marker in patients diagnosed with metastatic GC in Turkish population.
Materials and Methods: Clinical and laboratory data were collected and evaluated in the form of retrospective file scanning of One hundred forty-five patients with metastatic GC in Private Izmir Kent Hospital between 2017 and 2022. Analyzed factors included age, gender, precense of de novo or recurrent disease, first line treatment, ECOG-PS score, mGPS, CRP, and albumin levels, Progression Free Survival (PFS) and Overal Survival (OS).
Results: The median age at diagnosis was 67 years, the median progression-free survival (PFS) was 5.3 months, and the median overall survival (OS) was 9.5 months. OS was 15.1 months in patients with an mGPS of 0, 9.3 months in patients with an mGPS of 1, and 6.4 months in patients with an mGPS of 2 (*p=0.001).
Conclusions: mGPS is an easy to use and applicable parameter in Metastatic GC. High mGPS is poor prognostic factor for both PFS and OS in metastatic GC. |
|---|---|
| ISSN: | 2735-427X 2636-3402 |